# US 2021/0061875 A1 · Compositions and methods for treating autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061875 A1
- Document ID: US20210061875A1
- Status: Published application
- Kind: A1
- Application number: 16/958,539
- Filed: 2018-12-28
- Published: 2021-03-04
- Earliest claimed: 2017-12-29
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Jason R. LEES
- Web page: https://patentgrep.com/patent/US20210061875A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/414: {Nervous system antigens}
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are compositions comprising engineered CD8+ T cells that express a heterologous T cell receptor (TCR) having specificity for an autoantigen bound to a Major Histocompatibility Complex (MHC) Class II. Also provided are methods for the treatment of an autoimmune disease comprising administering the engineered CD8+ T cells. Also provided are methods for generating engineered CD8+ T cells that express a heterologous MHC Class II TCR, including methods of isolating autoantigen-MHC class II specific TCR for use in engineering CD8+ T cells for treatment.

## Claims

### Claim 1

An engineered CD8+ T cell comprising a heterologous nucleic acid encoding a T cell receptor (TCR), wherein the TCR binds to a self-antigen bound to a major histocompatibility complex (MHC) class II.

### Claim 2 (depends on 1)

The engineered CD8+ T cell of claim 1, wherein the engineered CD8+ T cell binds to a cell that expresses the self-antigen bound to MHC class II.

### Claim 3 (depends on 1)

The engineered CD8+ T cell of claim 1, wherein the engineered CD8+ T cell is able to lyse a cell that expresses the self-antigen bound to MHC class II.

### Claim 4 (depends on 2, 3)

The engineered CD8+ T cell of claim 2 or claim 3, wherein the cell that expresses the self-antigen bound to MHC class II is a dendritic cell, a macrophage, a monocyte, a microglial cell, or an astrocyte.

### Claim 5 (depends on 1, 2, 3, 4)

The engineered CD8+ T cell of any one of claims 1-4, wherein the MHC class II comprises H-2A, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR.

### Claim 6 (depends on 1, 2, 3, 4)

The engineered CD8+ T cell of any one of claims 1-4, wherein the MHC class II comprises HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR11, HLA-DR15 or HLA-DQ6.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The engineered CD8+ T cell of any one of claims 1-6, wherein the engineered CD8+ T cell decreases antigen specific activation of CD4+ cells when administered to a subject having an autoimmune disease.

### Claim 8 (depends on 7)

The engineered CD8+ T cell of claim 7, wherein the autoimmune disease is a neuroinflammatory disease.

### Claim 9 (depends on 7)

The engineered CD8+ T cell of claim 7, wherein the autoimmune disease is multiple sclerosis, diabetes, rheumatoid arthritis, myasthenia gravis, psoriasis, systemic lupus erythematosus, autoimmune thyroiditis, Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis, myocarditis, and polymyositis.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The engineered CD8+ T cell of any one of claims 1-9, wherein the self-antigen is a central nervous system (CNS) antigen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The engineered CD8+ T cell of any one of claims 1-9, wherein the self-antigen is selected from myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin associated glycoprotein (MAG), and proteolipid protein (PLP).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The engineered CD8+ T cell of any one of claims 1-9, wherein the self-antigen is MOG35-55.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The engineered CD8+ T cell of any one of claims 1-9, wherein the self-antigen is a diabetes mellitus associated antigen, a rheumatoid arthritis associated antigen, myocarditis associated self-antigen, or a thyroiditis associated antigen.

### Claim 14 (depends on 13)

The engineered CD8+ T cell of claim 13, wherein the self-antigen is insulin, chromogranin A, glutamic acid decarboxylase 1 (GAD67), glutamic acid decarboxylase 2 (GAD65) or islet-specific glucose-6-phosphatase catalytic subunit-related protein.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The engineered CD8+ T cell of any one of claims 1-14, wherein the TCR is derived from a CD4+ T cell.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The engineered CD8+ T cell of any one of claims 1-14, wherein the TCR is 2D2, B8, or bdc2.5.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The engineered CD8+ T cell of any one of claims 1-16, wherein the TCR is a chimeric antigen receptor (CAR) comprising (i) an extracellular antigen binding domain; (ii) a transmembrane domain; and (iii) an intracellular domain.

### Claim 18 (depends on 17)

The engineered CD8+ T cell of claim 17, wherein the extracellular antigen binding domain binds to the self-antigen bound to MHC Class II.

### Claim 19 (depends on 17, 18)

The engineered CD8+ T cell of any one of claims 17-18, wherein the extracellular antigen binding domain is derived from an antigen-binding portion of an antibody, a T cell receptor, or a B-cell receptor.

### Claim 20 (depends on 19)

The engineered CD8+ T cell of claim 19, wherein the T cell receptor is 2D2, B8 or bdc2.5.

### Claim 21 (depends on 17, 18, 19, 20)

The engineered CD8+ T cell of any one of claims 17-20, wherein the extracellular antigen binding domain comprises a single chain variable fragment (scFV).

### Claim 22 (depends on 21)

The engineered CD8+ T cell of claim 21, wherein the extracellular antigen binding domain comprises an scFv of 2D2 or B8.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The engineered CD8+ T cell of any one of claims 17-22, wherein the intracellular domain comprises one or more costimulatory domains.

### Claim 24 (depends on 23)

The engineered CD8+ T cell of claim 23, wherein the one or more costimulatory domains are selected from a CD28 costimulatory domain, a CD3ζ-chain, a 4-1BBL costimulatory domain, or any combination thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The engineered CD8+ T cell of any one of claims 1-24, wherein the nucleic acid encoding the TCR is operably linked to an inducible promoter or a conditional promoter.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for treating an autoimmune disease or condition, comprising administering an engineered CD8+ T cell of any one of claims 1-25 to a subject in need thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the autoimmune disease or condition is multiple sclerosis.

### Claim 28 (depends on 26)

The method of claim 26, wherein the autoimmune disease or condition is diabetes.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26-28, wherein administering the engineered CD8+ T cell decreases antigen specific activation of CD4+ cells in the subject, decreases tissue damage in the subject, and/or decreases autoimmune inflammation in the subject compared to no administration of the engineered CD8+ T cell.

### Claim 30 (depends on 26, 27, 28, 29)

The method of any one of claims 26-29, further comprising administering one or more additional therapeutic agents.

### Claim 31 (depends on 30)

The method of claim 30, wherein the one or more additional therapeutic agents is an anti-inflammatory agent or an immunosuppressive agent.

### Claim 32 (depends on 26, 27, 28, 29, 30, 31)

The method of any one of claims 26-31, wherein the CD8+ T cells are derived from an autologous donor or an allogenic donor.

### Claim 33 (depends on 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 26-32, wherein the subject is a human subject.

### Claim 34

A method for preparing an engineered CD8+ T cell, comprising transducing cytotoxic CD8+ T cells with a nucleic acid encoding a T cell receptor that binds to a self-antigen bound to a major histocompatibility complex (MEW) class II.

### Claim 35

A method for preparing an engineered CD8+ T cell, comprising transducing cytotoxic CD8+ T cells with a nucleic acid encoding a T cell receptor from isolated CD4+ T cells or a chimeric antigen receptor comprising an antigen binding domain thereof, wherein CD4+ T cells the bind to a self-antigen from a subject having an autoimmune disease.

### Claim 36

A method for preparing an engineered T cell comprising:
(a) isolating CD4+ T cells that bind to a self-antigen from a subject having an autoimmune disease;
(b) isolating nucleic acid encoding a T cell receptor from the isolated CD4+ T cells; and
(c) transducing cytotoxic CD8+ cells with nucleic acid encoding the T cell receptor from the isolated CD4+ T cells or a chimeric antigen receptor comprising an antigen binding domain thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the CD4+ T cells are MHC Class II-restricted T cells.

### Claim 38 (depends on 34, 35, 36, 37)

The method of any one of claims 34-37, further comprising expanding the transduced CD8+ cells.

### Claim 39 (depends on 38)

The method of claim 38, wherein expanding the transduced CD8+ cells comprises stimulation with and anti-CD3 and/or and anti-CD28 antibody.

### Claim 40 (depends on 34, 35, 36, 37, 38, 39)

The method of any one of claims 34-39, further comprising administering the transduced CD8+ cells to a subject in need thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the subject has an autoimmune disease or condition.

### Claim 42 (depends on 41)

The method of claim 41, wherein the autoimmune disease is multiple sclerosis or diabetes.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

An engineered CD8+ T cell according to any one of claims 1-25, for treating an autoimmune disease in a subject in need thereof.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of an engineered CD8+ T cells according to any one of claims 1-25, in the preparation of a medicament for treating an autoimmune disease.
